Back to journals
Academic JournalOpen Access

BMC Psychiatry

6 Papers Indexed in Blossom

Data updated

Research Footprint

BMC Psychiatry has 6 tracked papers indexed in Blossom (2022–2026) from 31 authors, most often covering Esketamine, Ketamine and Psilocybin, across Depressive Disorders, Suicidality and Microdosing.

Published Papers

Open Accessindividual

Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series

This prospective case series (n=8) examined repeated intranasal esketamine for people with treatment-resistant obsessive-compulsive disorder and comorbid major depressive disorder, and found clear improvement in depression and a smaller, more variable reduction in obsessive-compulsive symptoms. Depression improved earlier than OCD symptoms, and half of the participants met response criteria for each condition.

Published
Journal
BMC Psychiatry
Authors
López-Rodríguez, S., Segalàs, C., Real, E., Urretavizcaya, M., Bertolín, S., Menchón, J. M., del Pino Alonso, M.
Open Accessindividual

Single dose IV ketamine for adolescent suicidal ideation in the emergency department: a pilot randomized trial

This double-blind, randomised, placebo-controlled pilot trial (n=20) tested a single IV dose of ketamine for suicidal thoughts in adolescents attending the emergency department. It found the study was feasible and well tolerated, but ketamine did not clearly reduce suicidal ideation at 40 minutes, although fewer participants were admitted to hospital at the initial visit.

Published
Journal
BMC Psychiatry
Authors
Schlegelmilch, M., Plint, A. C., Barrowman, N., Gray, C., Crawford, T., Kutcher, S. A., Bhatt, M.
Open Accessindividual

Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response

This retrospective study (n=101) of inpatients with treatment-resistant depression (TRD) found that intranasal esketamine led to significant reductions in depression severity, with 28.8% achieving response and 19.3% remission. Older age was associated with greater remission likelihood, and extended induction beyond eight sessions appeared particularly beneficial for older patients and those with psychiatric comorbidities, with no serious adverse events observed.

Published
Journal
BMC Psychiatry
Authors
Baune, B. T., Rosemann, K., Hefter, D., Tonkul, M., Kavakbasi, E.
Open Accessindividual

Modulation of long-term potentiation following microdoses of LSD captured by thalamo-cortical modelling in a randomised, controlled trial

In a randomised, placebo-controlled trial of 80 healthy men given 10 µg LSD every third day for six weeks, standard ERP peak analyses showed no acute or cumulative effects on visually induced long-term potentiation. Dynamic causal modelling with a thalamo-cortical model, however, revealed laminar-specific changes in excitatory and inhibitory connectivity in primary visual cortex, suggesting the modelling approach is more sensitive than classic ERP measures for detecting microdose-induced plasticity.

Published
Journal
BMC Psychiatry
Authors
Murphy, R. J., Godfrey, K., Shaw, A. D., Muthukumaraswamy, S., Sumner, R. L.
Open Accessindividual

Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health

Using anonymous online semi‑structured interviews with 13 participants and Interpretive Phenomenological Analysis, this study found that users approached microdosing methodically as a self-directed attempt to support mental health and wellbeing and reported perceived cognitive, physical and social benefits, describing microdosing as a catalyst for positive change. The paper adds qualitative, experiential insight into the rationale and meaning of the microdosing phenomenon to inform future research on psychedelics and mental health.

Published
Journal
BMC Psychiatry
Authors
Ryan, R. S., Copello, A., Fox, A. P.
Paywallindividual

Expert Opinion on Psychedelic-Assisted Psychotherapy for People with Psychotic Symptoms

Experts concluded that blanket exclusion of people with psychotic symptoms from psychedelic trials is not universally justified and that highly supportive psychedelic-assisted psychotherapy may benefit some individuals. Treatment outcomes are likely to depend on factors such as symptom type, illness duration and severity, quality of the therapeutic alliance, trauma history and level of social support.

Published
Journal
BMC Psychiatry
Authors
La Torre, J. T., Mahammadli, M., Greenway, K. T., Williams, M.

Quick Facts

Papers Indexed
6
h-Index
151
Open Access
Yes
Publisher
Springer Nature
Country
United Kingdom
Website
Visit